According to Pfizer, this is the “first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.”
The phase 3 study of the pharmaceutical company, published in the journal The Lacent Neurology, details that this spray is capable of providing relief in just 15 minutes.
“The FDA approval of ZAVZPRET marks a significant advance for people with migraine who need to be pain-free and prefer alternative options to oral medications,” said Angela Hwang, Pfizer’s chief commercial officer and president of global biopharmaceutical businesses.
The study also notes that relief lasted up to 48 hours for some patients. In addition, no “serious adverse events in treated participants” were reported.
As a nasal spray with rapid drug absorption, ZAVZPRET offers an alternative treatment option for people who need pain relief or who cannot take oral medications due to nausea or vomiting, so they can return to normal function quickly. ”, commented Kathleen Mullin, associate medical director of the New England Institute of Neurology and Headache.